頭頸部がん治療薬の世界市場：市場規模（治療薬別・治療の種類別・投与経路別・エンドユーザー別・地域別）、将来予測

頭頸部がん治療薬の市場規模と予測

頭頸部がん治療薬の市場規模は、2024年に19億3,000万米ドルと評価され、2026年から2032年にかけて7.30%のCAGRで成長し、2032年には33億9,000万米ドルに達すると予測されています。

頭頸部がん治療薬には、口腔、咽頭、喉頭、鼻腔を含む頭頸部領域に発生するがんの管理と治療のために特別に設計された一連の医薬品治療が含まれます。

これには、化学療法、免疫療法、標的療法、放射線療法など、さまざまな治療カテゴリーが含まれます。

これらの薬剤は主に腫瘍学において、頭頸部がんと診断された患者の治療に使用されます。頭頸部がんは、タバコの使用、飲酒、ヒトパピローマウイルス（HPV）感染などの危険因子と関連していることが多いです。

頭頸部がんは、タバコの使用や飲酒、ヒトパピローマウイルス（HPV）感染などの危険因子と関連していることが多いです。

頭頸部がんに対する認識の高まりと精密医療の進歩が標的治療への需要を後押ししており、この市場は世界的に重大な健康問題に対処する上で不可欠なものとなっています。

世界の頭頸部がん治療薬市場の力学

世界の頭頸部がん治療薬市場を形成している主な市場力学には以下のものが含まれます：

主な市場促進要因

頭頸部がんの発生率の上昇：米国国立がん研究所（NCI）によると、2024年に米国で新たに診断される口腔がん、咽頭がん、喉頭がんの症例数は推定6万6,470件で、新規がん症例数全体の約3.4%を占めています。喫煙、飲酒、HPV感染などのライフスタイル要因による頭頸部がんの有病率の増加が、治療薬に対する需要を大きく牽引しています。

治療選択肢の進歩：薬剤開発における絶え間ない技術革新、特に標的療法や免疫療法における技術革新が治療効果を向上させ、採用率の上昇につながっています。

認知度の向上とスクリーニングプログラム：頭頸部がんに対する社会的認知の高まりや、早期発見と定期的な検診を推進する取り組みにより、より多くの患者が治療の選択肢を求めるようになっています。

研究開発投資の増加：製薬会社は新規治療法の研究や臨床試験に多大なリソースを割いており、市場の成長を促しています。

医療インフラの改善：特に発展途上地域における医療施設と腫瘍サービスの充実は、がん治療薬へのアクセスを容易にし、市場拡大に貢献しています。

主な課題

高額の治療費：先進的ながん治療に伴う高額な治療費は、患者のアクセスを制限し、治療の利用可能性に格差をもたらす可能性があります。

副作用と毒性：特定の抗がん剤に関連する重篤な副作用や長期的な毒性の可能性は、患者の治療レジメンへのアドヒアランスを妨げます。

規制上のハードル：新規治療薬に対する厳しい規制や長い承認プロセスは、市場参入を遅らせ、革新的な治療法へのタイムリーな患者アクセスを阻害する可能性があります。

新興市場における認知度の低さ：多くの新興諸国では、十分な認知度がなく、医療インフラも不十分であるため、利用可能な治療薬の導入が制限される可能性があります。

代替療法との競合：自然療法や補完療法を含む代替療法の台頭は、従来のがん治療薬に課題をもたらす可能性があります。

主要動向

個別化医療へのシフト：個々の遺伝子プロファイルやバイオマーカーに基づく個別化治療計画が重視されるようになり、頭頸部がん治療の有効性が高まっています。

治療におけるテクノロジーの統合：デジタルヘルス技術や遠隔医療を取り入れることで、患者の管理や治療レジメンへのアドヒアランスが向上しています。

コラボレーションとパートナーシップ：製薬企業、研究開発機関、医療提供者間の協力関係の強化により、医薬品開発が加速し、イノベーションが促進されます。

併用療法への注目：複数の治療手段を活用する併用療法の動向は、患者の予後改善と耐性菌の減少により人気を集めています。

バイオマーカー検査の利用増加：患者層別化のためのバイオマーカー検査の利用が増加しており、頭頸部がんにおける最も効果的な治療アプローチを決定するために不可欠となっています。

目次

第1章 世界の頭頸部がん治療薬市場：イントロダクション

• 市場概要
• 分析範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの分析手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の頭頸部がん治療薬市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界の頭頸部がん治療薬市場：治療薬別

• 概要
• PD阻害剤
• 微小管阻害剤
• EGFR阻害剤

第6章 世界の頭頸部がん治療薬市場：治療の種類別

• 概要
• 手術療法
• 放射線療法
• 標的療法
• 免疫療法
• 化学療法

第7章 世界の頭頸部がん治療薬市場：投与経路別

• 概要
• 注射剤
• 経口剤

第8章 世界の頭頸部がん治療薬市場：エンドユーザー別

• 概要
• 小売・専門薬局
• 病院薬局
• オンライン薬局

第9章 世界の頭頸部がん治療薬市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• その他の地域 (ROW)
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の頭頸部がん治療薬市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Bristol-Myers Squibb
• Merck & Co
• Eli Lilly
• Sanofi
• Merck Group
• AstraZeneca
• Pfizer
• Kura Oncology
• Lion Biotechnologies

第12章 付録

• 関連分析

Head And Neck Cancer Drugs Therapeutics Market Size And Forecast

Head And Neck Cancer Drugs Therapeutics Market size was valued at USD 1.93 Billion in 2024 and is projected to reach USD 3.39 Billion by 2032, growing at a CAGR of 7.30% from 2026 to 2032.

The head and neck cancer drugs therapeutics encompasses a range of pharmaceutical treatments specifically designed for the management and treatment of cancers that occur in the head and neck region, including the oral cavity, pharynx, larynx, and nasal passages.

This includes various therapeutic categories, such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy.

These drugs are used primarily in oncology to treat patients diagnosed with head and neck cancers, which are often associated with risk factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection.

The increasing prevalence of these cancers globally underscores the importance of this market, as effective treatment options are crucial for improving patient outcomes.

The rising awareness of head and neck cancers and advancements in precision medicine are propelling the demand for targeted therapies, making this market vital in addressing a significant health concern worldwide.

Global Head and Neck Cancer Drugs Therapeutics Market Dynamics

The key market dynamics that are shaping the global head and neck cancer drugs therapeutics market include:

Key Market Drivers

Rising Incidence of Head and Neck Cancers: According to the National Cancer Institute (NCI), an estimated 66,470 new cases of oral cavity, pharyngeal, and laryngeal cancers were diagnosed in the United States in 2024, representing approximately 3.4% of all new cancer cases. The increasing prevalence of head and neck cancers due to lifestyle factors such as smoking, alcohol consumption, and HPV infections is significantly driving demand for therapeutics.

Advancements in Treatment Options: Continuous innovations in drug development, particularly in targeted therapies and immunotherapies, are improving treatment efficacy, leading to higher adoption rates.

Growing Awareness and Screening Programs: Increased public awareness of head and neck cancers and initiatives promoting early detection and regular screenings are encouraging more patients to seek therapeutic options.

Increasing Research and Development Investments: Pharmaceutical companies are allocating significant resources to research and clinical trials for novel treatment modalities, stimulating market growth.

Improved Healthcare Infrastructure: The enhancement of healthcare facilities and oncology services, especially in developing regions, is facilitating access to cancer therapeutics and contributing to market expansion.

Key Challenges

High Treatment Costs: The elevated costs associated with advanced cancer therapies can limit patient access and result in disparities in treatment availability.

Side Effects and Toxicity: The potential for severe side effects and long-term toxicity associated with certain cancer drugs hinder patient adherence to treatment regimens.

Regulatory Hurdles: Stringent regulations and lengthy approval processes for new therapeutics can delay market entry and impede timely patient access to innovative treatments.

Limited Awareness in Emerging Markets: In many developing countries, insufficient awareness and inadequate healthcare infrastructure can restrict the adoption of available therapeutics.

Competition from Alternative Therapies: The rise of alternative treatment options, including natural and complementary therapies, can pose challenges for conventional cancer therapeutics.

Key Trends

Shift Towards Personalized Medicine: A growing emphasis on personalized treatment plans based on individual genetic profiles and biomarkers is enhancing the efficacy of head and neck cancer therapies.

Integration of Technology in Treatment: The incorporation of digital health technologies and telemedicine is improving patient management and adherence to treatment regimens.

Collaboration and Partnerships: Increased collaboration between pharmaceutical companies, research institutions, and healthcare providers is accelerating drug development and fostering innovation.

Focus on Combination Therapies: The trend of using combination therapies, which leverage multiple treatment modalities, is gaining popularity due to improved patient outcomes and reduced resistance.

Rising Use of Biomarker Testing: The growing utilization of biomarker testing for patient stratification is becoming essential for determining the most effective treatment approaches in head and neck cancer.

Global Head and Neck Cancer Drugs Therapeutics Market Regional Analysis

Here is a more detailed regional analysis of the global head and neck cancer drugs therapeutics market:

North America

North America is substantially dominating the Global Head and Neck Cancer Drugs Therapeutics Market and is expected to continue its dominance throughout the forecast period.

According to the American Cancer Society, an estimated 54,540 new cases of head and neck cancers are expected in the U.S. annually, highlighting the urgent need for effective treatment solutions.

The American Society of Clinical Oncology reports that since the FDA approval of pembrolizumab in 2016, the overall survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma has improved by 37%, compared to standard chemotherapy.

The North American market benefits from a well-established healthcare infrastructure, advanced research facilities, and significant investments in research and development by leading pharmaceutical companies.

This region is home to numerous biotech and pharmaceutical firms actively engaged in developing innovative therapies, including targeted treatments and immunotherapies specifically designed for head and neck cancers.

The presence of extensive clinical trial networks and regulatory agencies, such as the FDA, facilitates the timely approval and commercialization of new drugs.

The growing awareness of head and neck cancers and the availability of comprehensive treatment options contribute to an increasing patient population seeking therapies.

The North American market also faces challenges, including high treatment costs and the potential for disparities in access to care.

Despite these hurdles, the ongoing advancements in treatment modalities and the focus on personalized medicine position the North American head and neck cancer therapeutics market for sustained growth in the coming years.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the Global Head and Neck Cancer Drugs Therapeutics Market during the forecast period.

The increasing prevalence of head and neck cancers in countries like India, China, and Japan significantly contributes to the growing demand for effective treatment options.

In particular, the rise in tobacco and alcohol consumption, coupled with poor oral hygiene practices, has heightened the incidence of these cancers in the region.

The Asia-Pacific market is characterized by a rapidly evolving healthcare infrastructure, with substantial investments in healthcare facilities and services.

Governments in various countries are actively promoting cancer awareness campaigns and improving access to treatment, which is expected to lead to early diagnosis and better therapeutic outcomes.

The region also witnesses a surge in clinical trials focusing on innovative therapies, including targeted therapies and immunotherapies, tailored to the genetic and environmental factors prevalent in the population.

Partnerships between local pharmaceutical companies and global biotech firms are fostering research and development, accelerating the introduction of novel therapeutics into the market.

Global Head And Neck Cancer Drugs Therapeutics Market: Segmentation Analysis

The Global Head And Neck Cancer Drugs Therapeutics Market is Segmented on the basis of Therapeutic, Therapy Type, Route of Administration, End-User, and Geography.

Head And Neck Cancer Drugs Therapeutics Market, By Therapeutic

• PD Inhibitors
• Microtubule Inhibitors
• EGFR Inhibitors

Based on the Therapeutic Category, the Global Head and Neck Cancer Drugs Therapeutics Market is categorized into PD Inhibitors, Microtubule Inhibitors, and EGFR Inhibitors. The PD Inhibitors segment is experiencing significant growth owing to their role in enhancing the immune response against cancer cells by blocking programmed cell death pathways. This has led to improved survival rates for patients with head and neck cancers.

Head And Neck Cancer Drugs Therapeutics Market, By Therapy Type

• Surgery
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Chemotherapy

Based on the Therapy Type, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, and Chemotherapy. The Surgery segment dominates the market as surgery remains a primary treatment option, often employed to remove tumors and surrounding tissues, playing a crucial role in early-stage head and neck cancers.

Head And Neck Cancer Drugs Therapeutics Market, By Route of Administration

• Injectable
• Oral

Based on the Route of Administration, the Global Head and Neck Cancer Drugs Therapeutics Market is categorized into Injectable and Oral. Injectable segment dominates in the market. Injectable treatments are widely utilized in this market due to their rapid onset of action and ability to deliver higher concentrations of drugs directly into the bloodstream or tumors, ensuring effective management of cancer symptoms and treatment outcomes. This method is particularly important for medications that require close monitoring and precise dosing, such as chemotherapy and targeted therapies.

Head And Neck Cancer Drugs Therapeutics Market, By End User

• Retail & Specialty Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Based on the End User, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment significantly dominates in this market, as they provide essential medications directly to patients undergoing treatment in healthcare facilities. These pharmacies are often equipped to handle complex drug regimens, ensuring timely access to necessary therapies for managing head and neck cancer.

Head And Neck Cancer Drugs Therapeutics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is substantially dominating the Global Head and Neck Cancer Drugs Therapeutics Market and is expected to continue its dominance throughout the forecast period. According to the American Cancer Society, an estimated 54,540 new cases of head and neck cancers are expected in the U.S. annually, highlighting the urgent need for effective treatment solutions. The American Society of Clinical Oncology reports that since the FDA approval of pembrolizumab in 2016, the overall survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma has improved by 37%, compared to standard chemotherapy.

Key Players

The "Global Head and Neck Cancer Drugs Therapeutics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bristol-Myers Squibb, Merck & Co., Eli Lilly, Sanofi, Merck Group, AstraZeneca, Pfizer, Kura Oncology, and Lion Biotechnologies.

• This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Head And Neck Cancer Drugs Therapeutics Market Key Developments

• In April 2024, the OICR announced the launch of two new clinical trials as part of its Window-of-Opportunity (WOO) Network, which brought together Ontario researchers, doctors, and patients to investigate the biology of newly diagnosed and recurring malignancies.
• In March 2024, 3T Biosciences ("3T"), an immunotherapy company that aimed to change the future of treatment for solid tumors and other immune-mediated diseases, announced that it had formed multiple new collaborations with leading academic centers and principal investigators to fuel 3T's best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) pHLA target discovery platform.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY THERAPEUTIC

• 5.1 Overview
• 5.2 PD Inhibitors
• 5.3 Microtubule Inhibitors
• 5.4 EGFR Inhibitors

6 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY THERAPY TYPE

• 6.1 Overview
• 6.2 Surgery
• 6.3 Radiation Therapy
• 6.4 Targeted Therapy
• 6.5 Immunotherapy
• 6.6 Chemotherapy

7 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 Overview
• 7.2 Injectable
• 7.3 Oral

8 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY END-USER

• 8.1 Overview
• 8.2 Retail & Specialty Pharmacies
• 8.3 Hospital Pharmacies
• 8.4 Online Pharmacies

9 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Bristol-Myers Squibb
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Merck & Co
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Eli Lilly
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Sanofi
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Merck Group
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 AstraZeneca
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Pfizer
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Kura Oncology
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Lion Biotechnologies
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments

12 Appendix

• 12.1.1 Related Research